Literature DB >> 15844692

Effect of high-dose aspirin on Helicobacter pylori eradication.

Seung Ha Park1, Dong Il Park, Sang Hoon Kim, Hong Joo Kim, Yong Kyun Cho, In Kyung Sung, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Dong Keuk Keum.   

Abstract

We conducted a pilot study aimed at comparing the efficacy of the standard OAC (omeprazole-amoxicillin-clarithromycin) regimen with a combination of the OAC regimen and aspirin (OACA). Follow-up endoscopic findings showed that the previous ulcers were completely healed in all subjects. The eradication rates (per protocol) were 80.3% (49/61) in the OAC group and 86.7% (52/60) in the OACA group. The eradication rate was not significantly different between the two groups. The most common adverse event was a bad taste, and the overall adverse events were similar in the two groups. The combination of the OAC regimen and aspirin was not significantly superior to the standard OAC regimen, but it was well tolerated in a group of patients with peptic ulcer disease. Its potential for clinical use to augment the efficacy of H. pylori eradication may warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15844692     DOI: 10.1007/s10620-005-2547-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

1.  Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?

Authors:  G Maconi; F Parente; A Russo; L Vago; V Imbesi; G Bianchi Porro
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

2.  Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study.

Authors:  F Mégraud; N Lehn; T Lind; E Bayerdörffer; C O'Morain; R Spiller; P Unge; S V van Zanten; M Wrangstadh; C F Burman
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans.

Authors:  B Cryer; M Feldman
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

Review 4.  Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review.

Authors:  Hans-Joachim Ulmer; Andree Beckerling; Gudrun Gatz
Journal:  Helicobacter       Date:  2003-04       Impact factor: 5.753

5.  Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999.

Authors:  Joette M Meyer; Nancy P Silliman; Wenjin Wang; Nancy Y Siepman; Jennifer E Sugg; David Morris; Jie Zhang; Helen Bhattacharyya; Eileen C King; Robert J Hopkins
Journal:  Ann Intern Med       Date:  2002-01-01       Impact factor: 25.391

6.  Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States.

Authors:  M S Osato; R Reddy; S G Reddy; R L Penland; H M Malaty; D Y Graham
Journal:  Arch Intern Med       Date:  2001-05-14

Review 7.  Eradication of Helicobacter pylori infection.

Authors:  R H Hunt
Journal:  Am J Med       Date:  1996-05-20       Impact factor: 4.965

Review 8.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.

Authors:  M F Dixon; R M Genta; J H Yardley; P Correa
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

9.  Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial.

Authors:  L Laine; F Cominelli; R Sloane; V Casini-Raggi; M Marin-Sorensen; W M Weinstein
Journal:  Aliment Pharmacol Ther       Date:  1995-04       Impact factor: 8.171

10.  Helicobacter pylori, non-steroidal anti-inflammatory drugs and smoking in risk pattern of gastroduodenal ulcers.

Authors:  S J Konturek; W Bielański; M Płonka; T Pawlik; J Pepera; P C Konturek; J Czarnecki; A Penar; W Jedrychowski
Journal:  Scand J Gastroenterol       Date:  2003-09       Impact factor: 2.423

View more
  6 in total

1.  Aspirin increases susceptibility of Helicobacter pylori to metronidazole by augmenting endocellular concentrations of antimicrobials.

Authors:  Xiao-Ping Zhang; Wei-Hong Wang; Yu Tian; Wen Gao; Jiang Li
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

2.  Efficacy of serology driven "test and treat strategy" for eradication of H. pylori in patients with rheumatic disease in the Netherlands.

Authors:  H T J I de Leest; K S S Steen; W F Lems; M A F J van de Laar; A M Huisman; S W Kadir; H H M L Houben; P J Kostense; E J Kuipers; B A C Dijkmans; Y J Debets-Ossenkopp
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-04       Impact factor: 3.267

3.  Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?

Authors:  Eun Jeong Gong; Sung-Cheol Yun; Hwoon-Yong Jung; Hyun Lim; Kwi-Sook Choi; Ji Yong Ahn; Jeong Hoon Lee; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

4.  Assessment of Helicobacter pylori eradication in patients on NSAID treatment.

Authors:  Harald E Vonkeman; Htji Deleest; Mafj van Delaar; J Vanbaarlen; Kss Steen; Wf Lems; Jwj Bijlsma; Ej Kuipers; Hhml Houben; M Janssen; Bac Dijkmans
Journal:  BMC Gastroenterol       Date:  2012-09-24       Impact factor: 3.067

5.  Adding diclofenac to Helicobacter pylori eradication regimen.

Authors:  Mohammad Hasan Emami; Akbar Arjmandpour; Hamed Daghaghzadeh; Hojatollah Rahimi; Ali Toghiani; Peyman Adibi
Journal:  Adv Biomed Res       Date:  2015-07-27

Review 6.  Facing resistance of H.pylori infection.

Authors:  Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2011
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.